Allogeneic Nicotinamide (NAM)-enabled Cell Development Service

Online Inquiry

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Allogeneic Nicotinamide (NAM)-enabled Cell Development Service: Pioneering Efficient Cell Therapies

The development of cell therapies has revolutionized the landscape of medical treatments for cancer and other hematological disorders. A notable advancement in this field is the utilization of allogeneic nicotinamide (NAM)-enabled cell development, a technology that enhances and expands innate immune cells to offer potentially curative options. Creative Biolabs has embraced this cutting-edge approach to drive improvements in cell-based immunotherapies for solid tumors and blood cancers.

Allogeneic Nicotinamide (NAM)-enabled Cell Development Service at Creative Biolabs

Creative Biolabs has integrated proprietary NAM technology to transform the expansion and metabolic modulation of multiple cell types, including stem cells and natural killer (NK) cells. NAM, also known as nicotinamide, plays a crucial role in enhancing cell functionality and maintaining an active phenotype during the expansion phase. This enables the generation of highly potent and resilient cells tailored for allogeneic therapies. The application of NAM technology is fundamental in improving the metabolic fitness of cells, ensuring sustained activity and enhancing their therapeutic potential.

Step-by-step Workflow

Cell Sourcing and Preparation

We source stem cells from adult donors, capitalizing on their heterogeneity and plasticity.

NAM Expansion and Modulation

By employing our proprietary NAM technology, we expand the cells while maintaining their active phenotype and enhancing their metabolic fitness.

Genetic Modifications

For targeted immunotherapies, we incorporate CARs (Chimeric Antigen Receptors) into NK cells to improve specificity and cytotoxicity against tumor antigens.

Quality Assurance

Each batch undergoes rigorous testing for potency, safety, and efficacy to meet GMP standards.

Preclinical Application

Our products are tested in preclinical validation to ensure they meet therapeutic benchmarks before commercialization.

Highlights of Our Strategy

Enhanced Cell Functionality

Creative Biolabs' NAM-enabled technology has been proven to prevent cell exhaustion, enhance cytotoxic activity, generate protective effects against oxidative stress, and improve homing to lymphoid tissues. This ensures that the expanded cells retain their intrinsic properties and exhibit superior functionality.

Overcoming Immunotherapies' Limitations

Traditional NK cell therapies often face challenges such as the immunosuppressive tumor microenvironment and inefficient trafficking. Creative Biolabs addresses these limitations through genetic modification strategies, such as the development of CAR NK cells. By leveraging NAM technology, our engineered NK cells demonstrate increased cytotoxicity against specific cancer cells.

Scalable and GMP-compliant Production

Our service employs a reliable, scalable, and GMP-compliant culture method, ensuring the production of highly functional NK cells. This approach not only guarantees quality but also facilitates the translation from pre-clinical development to clinical applications.

Frequently Asked Questions

Q1: How does NAM technology improve cell potency?

A1: The unique properties of NAM allow for the modulation of cell metabolism, preventing exhaustion, and enhancing cytotoxic effects, particularly relevant for NK cells and stem cells.

Q2: Why choose allogeneic cells over autologous cells?

A2: Allogeneic cells can be sourced from donors, providing a readily available and scalable source, unlike autologous cells that require individualized patient-derived cells.

Partnering with Creative Biolabs ensures access to the forefront of cell therapy innovations. Our NAM-enabled cell development services promise not only high-quality products but also a collaborative journey from research to clinical applications. By working with us, clients can leverage our expertise and state-of-the-art technology to develop superior cell-based therapies that address the unmet clinical needs of cancer patients and those with severe hematological diseases.